Estrogen and thrombosis: Controversies and common sense
- 11 May 2011
- journal article
- review article
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 12 (2) , 77-84
Abstract
Soon after the introduction of hormonal oral contraceptive agents reports of thrombotic complications appeared. In the past several decades, large epidemiological studies helped defined these risks for both arterial and venous complications. Clinicians can assess a patient’s risk of thrombosis by both composition of the agent and patients’ personal risk factors. For women with bleeding disorders these prothrombotic changes can help decrease bleeding complications. There is now also abundant data on future management of patients with estrogen related thrombosis.Keywords
This publication has 65 references indexed in Scilit:
- Epidemiology of the contraceptive pill and venous thromboembolismThrombosis Research, 2011
- Risk assessment for recurrent venous thrombosisThe Lancet, 2010
- Levonorgestrel-Releasing Intrauterine System or Medroxyprogesterone for Heavy Menstrual BleedingObstetrics & Gynecology, 2010
- Contraceptive Hormone Use and Cardiovascular DiseaseJACC, 2009
- Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosisContraception, 2008
- Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disordersFertility and Sterility, 2008
- A Benefit-Risk Review of Systemic Haemostatic AgentsDrug Safety, 2008
- Hormone therapy and thromboembolic diseaseCurrent Opinion in HIV and AIDS, 2007
- Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) StudyStroke, 2002
- Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control studyThe Lancet, 1995